Detailansicht

Wissensnetz

Person

Andreas Hartkopf (1979-)

Arzt

Name	Andreas Hartkopf
Zeit	1979- (Lebensdaten)
Ort	Heidelberg (Geburtsort) Deutschland
Geschlecht	männlich
Beruf	Arzt (charakteristischer Beruf) Gynäkologe
Variante	Andreas D. Hartkopf Andreas Daniel Hartkopf A. D. Hartkopf
Beziehung	Humanmedizin mit betriebswirtschaftlicher Qualifikation (Master) (Studienfach)
Weitere Angaben	Diss. Medizinische Fakultät der Univ. Heidelberg. - Habilitation an der Medizinischen Fakultät der Universität Tübingen (Fach Gynäkologie und Geburtshilfe)
Datensatztyp	Person
GND-Nummer	139124101
Datensatz-ID	139124101
Beteiligt an alle anzeigen Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024 Implementation and evaluation of a breast cancer disease model using real-world claims data in Germany from 2010 to 2020 Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer Insights from ASCO 2023 Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patientinnen mit nicht operablem, metastasiertem HER2-low Mammakarzinom Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patientinnen mit nicht operablem, metastasiertem HER2-low Mammakarzinom Update breast cancer 2023 Part 1 – early stage breast cancer Update breast cancer 2023 Part 1: early stage breast cancer Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients Update breast cancer 2020 part 5: moving therapies from advanced to early breast cancer patients HER2-targeted therapy influences CTC status in metastatic breast cancer Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer ClinOmicsTrailbc : a visual analytics tool for breast cancer treatment stratification Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study Update breast cancer 2019 part 1 – implementation of study results of novel study designs in clinical practice in patients with early breast cancer Gynäkologische Onkologie : Prolog für die DKG: Olaf Ortmann, Geleitwort für die DGS: Rüdiger Schulz-Wendtland, Prolog für die AGO: Tanja Fehm Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ The impact of single tumor cell dissemination on individualized systemic breast cancer treatment The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread Onkolytische H-1-Parvoviren in Kombination mit ionisierender Strahlung : Untersuchung zytotoxischer Effekte in Zellkulturen humaner Glioblastome

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Update Breast Cancer 2024 Part 1 – Expert Opinion on Advanced Breast Cancer

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2024

Implementation and evaluation of a breast cancer disease model using real-world claims data in Germany from 2010 to 2020

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

Insights from ASCO 2023

Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom

Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom

Update breast cancer 2023 Part 1 – early stage breast cancer

Update breast cancer 2023 Part 1: early stage breast cancer

Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients

Update breast cancer 2020 part 5: moving therapies from advanced to early breast cancer patients

HER2-targeted therapy influences CTC status in metastatic breast cancer

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer

ClinOmicsTrailbc : a visual analytics tool for breast cancer treatment stratification

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

Update breast cancer 2019 part 1 – implementation of study results of novel study designs in clinical practice in patients with early breast cancer

Gynäkologische Onkologie : Prolog für die DKG: Olaf Ortmann, Geleitwort für die DGS: Rüdiger Schulz-Wendtland, Prolog für die AGO: Tanja Fehm

Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer

Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients

Detection and clinical relevance of hematogenous tumor cell dissemination in patients with ductal carcinoma in situ

The impact of single tumor cell dissemination on individualized systemic breast cancer treatment

The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse

Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread

Onkolytische H-1-Parvoviren in Kombination mit ionisierender Strahlung : Untersuchung zytotoxischer Effekte in Zellkulturen humaner Glioblastome